In hepatocellular carcinoma, Notch 3 activation specifically was shown to contribute to doxorubicin resistance through a mechanism involving p53 regulation and this effect could be abrogated by silencing Notch 3 [268]. Here, NOTCH3 is linked to hepatocellular carcinoma.